Lipopolysaccharide and Polyribonucleotide Activation of Macrophages: Implications for a Natural Triggering Signal in Tumor Cell Killing
Overview
Authors
Affiliations
There is evidence that activation of macrophages for tumor cell killing can involve either two signals (interferon/lipopolysaccharide, for example) or one signal (lipopolysaccharide or double-stranded RNA, for example). We investigated the apparent one-signal activation of bone marrow-derived macrophages for P815 mastocytoma killing by treatment with lipopolysaccharide (LPS) or by the synthetic double-stranded polyribonucleotide polyinosinic acid-polycytidylic acid (poly I:C). We found that "direct" activation of macrophages by either LPS or poly I:C was still a two-signal process. Based on antibody neutralizations, the first signal was probably mediated by LPS or poly I:C induced alpha/beta interferon in the macrophage cultures, and the second signal was that of a direct effect of the LPS or poly I:C on the cell. The fact that poly I:C can provide the triggering signal for macrophage activation suggests a possible role for double-stranded RNA structures in macrophage triggering. Such double-stranded RNA requirements could be met by single-stranded RNAs that possess significant double-strandedness in their structures.
Toll-Like Receptor Ligands and Interferon-γ Synergize for Induction of Antitumor M1 Macrophages.
Muller E, Christopoulos P, Halder S, Lunde A, Beraki K, Speth M Front Immunol. 2017; 8:1383.
PMID: 29123526 PMC: 5662546. DOI: 10.3389/fimmu.2017.01383.
Bashir N, Kounsar F, Mukhopadhyay S, Hasnain S Immunology. 2010; 130(1):34-45.
PMID: 20201990 PMC: 2855791. DOI: 10.1111/j.1365-2567.2009.03196.x.
A novel autoimmune pancreatitis model in MRL mice treated with polyinosinic:polycytidylic acid.
Qu W, Miyazaki T, Terada M, Okada K, Mori S, Kanno H Clin Exp Immunol. 2002; 129(1):27-34.
PMID: 12100019 PMC: 1906409. DOI: 10.1046/j.1365-2249.2002.01881.x.
Hayes M, Zoon K Infect Immun. 1993; 61(8):3222-7.
PMID: 8335353 PMC: 280991. DOI: 10.1128/iai.61.8.3222-3227.1993.
Lake F, Noble P, Henson P, Riches D J Clin Invest. 1994; 93(4):1661-9.
PMID: 7512988 PMC: 294209. DOI: 10.1172/JCI117148.